Vasopressin-induced vasoconstriction is dependent on MAPKerk1/2 phosphorylation

Fundamental and Clinical Pharmacology

Volumn 18, Issue 1, 2004, Pages 45-50

  Streefkerk, Jörn O ^a   Hoogaars, Willem M H ^a   Christoffels, Vincent M ^a   Sand, Carsten ^a   Pfaffendorf, Martin ^a   Peters, Stephan L M ^a   Van Zwieten, Pieter A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Extracellular signal regulated kinase; Isometric force; Mitogen activated protein kinase; Rat aorta; Vascular smooth muscle; Vasopressin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; THORACIC AORTA; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; BLOTTING, WESTERN; BUTADIENES; ENZYME INHIBITORS; FLAVONOIDS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; NITRILES; PHOSPHORYLATION; POTASSIUM; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 1042299809     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00221.x     Document Type: Article

References (33)

1. Birnbaumer M. Vasopressin receptors. Trends Endocrinol. Metab. (2000) 11 406-410.
2. Thibonnier M., Coles P., Thibonnier A., Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu. Rev. Pharmacol. Toxicol. (2001) 41 175-202.
3. Li X., Kribben A., Wieder E.D., Tsai P., Nemenoff R.A., Schrier R.W. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268. Hypertension (1994) 23 217-222.
4. Serradeil-Le Gal C., Herbert J.M., Delisee C. et al. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am. J. Physiol. (1995) 268 H404-H410.
5. Tahara A., Tomura Y., Wada K. et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J. Cardiovasc. Pharmacol. (1997) 30 759-766.
6. Tahara A., Tsukada J., Tomura Y. et al. Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells. J. Hypertens. (2002) 20 1807-1814.
7. Kribben A., Wieder E.D., Li X. et al. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am. J. Physiol. (1993) 265 C939-C945.
8. Haq S., Choukroun G., Lim H. et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation (2001) 103 670-677.
9. Flesch M., Margulies K.B., Mochmann H.C., Engel D., Sivasubramanian N., Mann D.L. Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation (2001) 104 2273-2276.
10. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. (1999) 79 143-180.
11. Hoefen R.J., Berk B.C. The role of MAP kinases in endothelial activation. Vasc. Pharmacol. (2002) 38 271-273.
12. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 298 1911-1912.
13. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. (1995) 9 726-735.
14. Xin X., Yang N., Eckhart A.D., Faber J.E. Alpha1D-adrenergic receptors and mitogen-activated protein kinase mediate increased protein synthesis by arterial smooth muscle. Mol. Pharmacol. (1997) 51 764-775.
15. Abe J., Baines C.P., Berk B.C. Role of mitogen-activated protein kinases in ischemia and reperfusion injury: the good and the bad. Circ. Res. (2000) 86 607-609.
16. Laniyonu A.A., Saifeddine M., Yang S.G., Hollenberg M.D. Tyrosine kinase inhibitors and the contractile action of G-protein-linked vascular agonists. Can. J. Physiol. Pharmacol. (1994) 72 1075-1085.
17. Watts S.W. Serotonin activates the mitogen-activated protein kinase pathway in vascular smooth muscle: use of the mitogen-activated protein kinase kinase inhibitor PD098059. J. Pharmacol. Exp. Ther. (1996) 279 1541-1550.
18. Watts S.W., Florian J.A., Monroe K.M. Dissociation of angiotensin II-stimulated activation of mitogen-activated protein kinase kinase from vascular contraction. J. Pharmacol. Exp. Ther. (1998) 286 1431-1438.
19. Touyz R.M., He G., Deng L.Y., Schiffrin E.L. Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. Circulation (1999) 99 392-399.
20. Roberts R.E. Role of the extracellular signal-regulated kinase (Erk) signal transduction cascade in alpha(2) adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein. Br. J. Pharmacol. (2001) 133 859-866.
21. Ratz P.H. Regulation of ERK phosphorylation in differentiated arterial muscle of rabbits, H114-H123. Am. J. Physiol. Heart Circ. Physiol. (2001) 281 H114-H123.
22. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. (2000) 351 95-105.
23. Granot Y., Erikson E., Fridman H. et al. Direct evidence for tyrosine and threonine phosphorylation and activation of mitogen-activated protein kinase by vasopressin in cultured rat vascular smooth muscle cells. J. Biol. Chem. (1993) 268 9564-9569.
24. Okada K., Sasaki R., Ishikawa S., Saito T. Distinct inhibition by non-peptide and peptide arginine vasopressin antagonists of vasopressin-induced activation of mitogen-activated protein kinase in cultured rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1994) 200 1155-1160.
25. Kamakura S., Moriguchi T., Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. (1999) 274 26563-26571.
26. Borsch-Haubold A.G., Pasquet S., Watson S.P. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J. Biol. Chem. (1998) 273 28766-28772.
27. Martinez M.C., Vila J.M., Aldasoro M., Medina P., Flor B., Lluch S. Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin. Br. J. Pharmacol. (1994) 113 419-424.
28. Millette E., Lamontagne D. Endothelium-dependent and NO-mediated desensitization to vasopressin in rat aorta. Br. J. Pharmacol. (1996) 119 899-904.
29. Hedges J.C., Oxhorn B.C., Carty M., Adam L.P., Yamboliev I.A., Gerthoffer W.T. Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle. Am. J. Physiol. Cell. Physiol. (2000) 278 C718-C726.
30. D'Angelo G., Adam L.P. Inhibition of ERK attenuates force development by lowering myosin light chain phosphorylation. Am. J. Physiol. Heart Circ. Physiol. (2002) 282 H602-H610.
31. Francis G.S., Benedict C., Johnstone D.E. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82 1724-1729.
32. Rouleau J.L., Packer M., Moye L. et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol. (1994) 24 583-591.
33. de Paula R.B., Plavnik F.L., Rodrigues C.I. et al. Age and race determine vasopressin participation in upright blood pressure control in essential hypertension. Ann. N. Y. Acad. Sci. (1993) 689 534-536.